Priscilla Chan and Mark Zuckerberg are pushing the boundaries of biotechnology through their Chan Zuckerberg Initiative (CZI) Biohub, aiming to cure all diseases. The Biohub is backed by substantial funding, with a budget of $1 billion per year for the next 10 to 15 years. They recently acquired EvoScale, significantly boosting their computational power with a new 10,000 GPU cluster. This setup supports projects like the Human Cell Atlas and aims to build detailed virtual models of human cells and immune systems, which are essential for understanding and manipulating biological processes. The Biohub’s work is based on previous successes, such as the Human Genome Project and AlphaFold, which mapped human DNA and protein structures, respectively. The initiative plans to tackle significant medical challenges, such as neurodegenerative and autoimmune diseases. Chan emphasizes the importance of understanding the immune system, noting that insights could lead to innovative therapies like CAR T-cell treatments for cancer and new approaches for diseases like multiple sclerosis and possibly dementia. Three new models have been introduced on their virtual cells platform: VariantFormer, which connects genetic variations to gene activity; CryoLens, a model for structural analysis in cryo-electron tomography; and scLDM, capable of generating detailed single-cell data. These tools complement existing models focused on gene regulatory networks and biological reasoning, creating a comprehensive framework for AI-driven research in biology. The Biohub’s interdisciplinary collaboration aims to redefine how we approach health and disease, making strides toward a future where we can predict, prevent, and treat illnesses more effectively.